Linked Life Data

18540367

Source:http://linkedlifedata.com/resource/pubmed/id/18540367

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-6-10
pubmed:abstractText
The understanding on the pathophysiology of Guillain-Barré syndrome (GBS) has been significantly advanced for the past few years, and the contribution of Japanese researchers to it is worth mentioning. In axonal GBS (AMAN), transmission failure of a peripheral nerve occurs when anti-ganglioside antibody which is specifically formed based on the polymorphism of C. jejuni enters through the blood-nerve barrier and damages the node of Ranvier and its surrounding structures. Electrophysiologically, patients with AMAN demonstrate distal conduction failure, but that finding may improve rapidly by immunomodurating therapy suggesting distal conduction failure. The mainstream therapy of GBS is still intravenous immunoglobulin (IVIg) and plasma exchange. However, clinical trials to assess effectiveness of other immunotherapy have been actively conducted.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1181-3
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Overview of new research findings].
pubmed:affiliation
Department of Neurology, Tokushima University.
pubmed:publicationType
Journal Article, English Abstract, Review